A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs GS 9876 (Primary) ; Filgotinib
  • Indications Rheumatoid arthritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 16 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Sep 2017.
    • 16 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2017.
    • 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top